How India Exports Roxithromycin to the World

As of March 2026, Roxithromycin does not have any approved Abbreviated New Drug Applications (ANDAs) listed in the FDA's Orange Book. This absence indicates that Roxithromycin is not currently approved for marketing in the United States. Consequently, there are no recent approvals, import alerts, or established regulatory pathways for Roxithromycin in the U.S. market. Given that 78 Indian exporters are active in the Roxithromycin market, the lack of U.S. approval suggests a strategic focus on markets with existing regulatory acceptance.

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicinal products. Roxithromycin has received marketing authorization in several EU member states, indicating compliance with the EMA's stringent requirements for safety, efficacy, and quality. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Roxithromycin, ensuring adherence to UK-specific regulatory standards. Manufacturers exporting to these regions must comply with Good Manufacturing Practice (GMP) guidelines as stipulated by the EMA and MHRA to maintain market access.

Roxithromycin is not listed on the World Health Organization's (WHO) Model List of Essential Medicines as of the 24th edition published in September 2025. This exclusion suggests that, while effective, Roxithromycin is not considered essential for addressing priority health needs on a global scale. Regarding pharmacopoeial standards, Roxithromycin is included in the British Pharmacopoeia (BP) and the European Pharmacopoeia (EP), providing standardized quality benchmarks for its production and quality control.

In India, Roxithromycin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. This classification mandates that Roxithromycin can only be sold with a valid prescription from a registered medical practitioner. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for Roxithromycin, allowing market-driven pricing within the country. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

Roxithromycin's primary patents have expired, leading to the availability of generic versions in various markets. This expiration has intensified competition among manufacturers, particularly in regions where Roxithromycin holds significant market share. The presence of 78 active Indian exporters underscores the competitive landscape and the strategic importance of Roxithromycin in India's pharmaceutical export portfolio.

In May 2025, the WHO updated its Model List of Essential Medicines, and Roxithromycin was not included in the 24th edition. This decision reflects the organization's assessment of global health priorities and the availability of alternative treatments.

In January 2026, the WHO emphasized the importance of essential medicines in treating priority health-care needs, highlighting the need for medicines to be available, affordable, and of assured quality at all times. While Roxithromycin is not listed as an essential medicine, its role in treating bacterial infections remains significant in various markets. (who.int)

These developments underscore the dynamic nature of the pharmaceutical industry and the importance of staying informed about regulatory changes and market trends.

Roxithromycin, a macrolide antibiotic, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where China controls approximately 70–80% of global KSM supply and 60–70% of intermediate supply, making it a critical player in the pharmaceutical supply chain.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, the closure of the Strait of Hormuz disrupted the supply of essential chemicals and petrochemicals from the Middle East, leading to increased costs and logistical challenges for API manufacturers in India. This disruption underscores the risks associated with over-reliance on specific regions for critical raw materials.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of Roxithromycin account for 70.6% of total exports, with BRAWN LABORATORIES LIMITED alone contributing 30.3%. This high supplier concentration poses a significant risk, as any operational or compliance issues within these key companies could disrupt the entire supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical APIs and KSMs. Notably, in November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a significant step towards self-reliance.

The closure of the Strait of Hormuz in March 2026 has had profound implications for global supply chains, including the pharmaceutical sector. Approximately 20% of the world's oil passes through this strait, and its disruption has led to increased fuel prices and shipping delays. For Indian pharmaceutical exports, this means higher transportation costs and potential delays in delivering products like Roxithromycin to key markets.

Additionally, the Red Sea and Suez Canal have experienced instability due to regional conflicts, further complicating shipping routes. These disruptions have forced shipping companies to reroute vessels around the Cape of Good Hope, adding significant time and cost to deliveries.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Roxithromycin and its raw materials to reduce dependency on a limited number of exporters.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for KSMs and APIs to decrease reliance on imports, particularly from China.

• Strengthen Supply Chain Resilience: Develop contingency plans and maintain strategic reserves of critical raw materials to buffer against geopolitical disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track international events that could impact supply chains and proactively adjust strategies accordingly.

• Leverage Government Initiatives: Utilize schemes like the PLI to bolster domestic production and reduce import dependence.

RISK_LEVEL: HIGH